COVID-19 resources / Clinical Research Insights and News

The Cohortias Blog

Stay informed

COVID-19 resources

Cohortias is bringing clinical research to Latin America, now proud to participate in COVID-19 clinical trials.

Our archive includes insights from our experts as they discuss lessons learned over the past three months in managing COVID-19’s impact on trials in Latin America and around the world.

Our blog posts provide insights into what companies should be doing now to prepare for the upcoming ‘new normal’.

psoriasis

Cohortias – Positive data from new psoriasis therapy trial.

In the study, NDI-034858 achieved statistical significance in a greater number of patients, with more reaching PASI-75.

Brazil

Cohortias – Opportunities and Challenges in Brazil.

Brazil is a large country with over 200 million inhabitants, making it the largest population in Latin America.

colitis

Cohortias – New ulcerative colitis therapy trial

The Phase IIb study will assess the efficacy and safety of three active dose regimens of MORF-057 in ulcerative colitis patients.

clinical research

Clinical Research in Latin America 2022 – Cohortias is the Clinical Research Organization.

CRO South America – Cohortias continue to grow in South America. We are a local based Clinical Research Organization with one goal: expand clinical research access across Latin American countries.

COVID-19 Research - Free Consultation

The clinical development journey is fraught with pitfalls and roadblocks; COVID-19 has almost overnight added to the complexity. Innovations, technologies and reinvented processes can help. Our experienced team of experts shares experiences, lessons learned and tips to help you mitigate risk in the current environment while implementing some of the industry’s latest innovations.

covid clinical trials

The presence of clinical research in Latin America has been growing steadily for the last decade, mainly because of cost effectiveness, excellent patient recruitment and the emergence of FDA approved regulatory agencies.